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THE OBJECTIVE of this workshop was to
evaluate the current status of research on
the detection and isolation of antigens
from chemically induced experimental
animal tumours and human tumours,
particularly with regard to assessing the
present development and application of
objective assays. In introducing the meet-
ing, the concept that tumour-specific
antigens (TSA) and tumour-associated
antigens (TAA) may not necessarily be
exclusive to the transformed cell was
developed, and evidence was presented
that primary rat sarcomas induced by
3-methylcholanthrene (MCA) were often
polyclonal (Baldwin). In these tests and
other studies, antigens were defined by
the reaction they provoke in the tumour-
bearing host or in syngeneic recipients of
transplanted tumour or tumour extracts.
Conversely, Bagshawe pointed out that
clinical tumour immunology was almost
entirely based upon the use of appro-
priately absorbed heteroantisera which,
in a number of situations, were of value in
monitoring for malignant disease. How-
ever, although recognized to be of low
clinical utility, techniques such as leuco-
cyte migration inhibition (MLI), leuco-
cyte-adherence inhibition (LAI), macro-
phage electrophoretic mobility (MEM),
cell-mediated cytotoxicity (CMC) and
delayed hypersensitivity reaction (DHR)
assays were shown to discriminate be-
tween cancer patients and non-malignant
or healthy controls by their measurement
of host responses to common TAA
(Bagshawe, Thomson, Pasternak, Bubenik,
Vose, Fossati and Dickinson). Indeed,
Vose demonstrated that lymphocytes iso-
lated from the blood of patients with lung
tumours showed CMC for freshly isolated
autologous lung-tumour cells similar to
that found with many experimental
tumours, although whether this repre-
sented the response to individual TSA or
a genetically restricted reaction to com-
mon TAA was unknown.
Sjogren summarized the assays cur-
rently available for the demonstration of
antigens against which the host may
respond. These fell into 3 broad categories,
and included (a) in vivo assays such as the
induction of tumour rejection or preven-M. R. PRICE, D. HANNANT, M. J. EMBLETON AND R. W. BALDWIN
tion of tumorigenicity by immunization
against tumour prior to carcinogen treat-
ment, (b) detection of antigens by a com-
bination of in vivo and in vitro techniques
in which the recipient is virgin as far as
the tumour is concerned (e.g. neutraliza-
tion tests with lymphocytes or serum from
immune donors), (c) detection of humoral
antibodies to tumour antigens. Mono-
clonal antibodies were considered to repre-
sent a most important development with
regard to this latter approach, and Carrel
proposed that the antigens detected with
these reagents could be divided into 3
classes: Class 1 antigens restricted to
autologous tumour cells; Class 2 antigens
common to several allogeneic tumours,
and Class 3 antigens not restricted to
tumour cells. With conventional hetero-
antisera, virtually all antibodies are re-
active against Class 3 antigens and exten-
sive absorption is frequently necessary to
reveal antibodies to Class 1 and 2 antigens.
It was noted that the production of
monoclonal antibodies against TAA on
colo-rectal carcinoma, melanoma, chronic
lymphocytic leukaemia, astrocytoma as
well as CEA and HCG had already been
reported in the literature, exemplifying
current progress with these reagents. The
advantage of using partially purified
antigenic fractions for the immunization
before cell fusion was emphasized, to
decrease the number of hybridomas pro-
ducing antibodies to Class 3 antigens
(Carrel). Lennox and Embleton sum-
marized the results of studies using mono-
clonal antibodies to examine the antigenic
profile of MCA-induced murine sarcomas
and spontaneously arising rat mammary
carcinomas, respectively. With the murine
sarcomas, it was now possible to investi-
gate problems such as whether TAA are
new products or "misplaced" antigens by
using cloned tumour cell lines, although
difficulties were encountered with respect
to the low affinity of these antibodies
(Lennox). With one rat mammary carcin-
oma, the specificity of a high-titre mono-
clonal antibody was found to be identical
to that of antibodies produced by con-
ventional immunization of syngeneic rats
(Embleton).
In introducing the topic of isolation and
characterization of antigens, Rogers illus-
trated a number of problems with results
on the murine tumours Meth A, RBL5 and
mKSA, and he suggested that having
chosen a suitable source for antigen
extraction (cells, serum or urine) and an
appropriate antigen assay, two strategies
could be adopted: (a) purify the TSA and
assay it directly (e.g. by its capacity to
induce tumour rejection) and (b) purify
a component which is a likely candidate
for the TSA but is more easily isolated and
assayed (e.g. alien histocompatibility anti-
gens). With purified antigens, before full
characterization can be contemplated, it
was considered necessary to establish both
homogeneity by biochemical criteria and
to demonstrate the retention ofhigh levels
of antigenic activity (although this may
be difficult to quantitate, and often there
are considerable losses during antigen
purification) (Rogers). DeLeo defined the
unique TSA on the MCA-induced sarcoma,
Meth A, in extensive in vitro cytotoxicity
assays with syngeneic immune serum, and
he posed the question whether this deter-
minant was equivalent to the component
inducing tumour rejection. Among the
many combinations tested, only one cross
reaction between anti-Meth A and a non-
tumorigenic variant of a murine tumour
cell line, lIA, was detected, and it was
determined that this cell line had the
capacity to immunize against Meth A
sarcoma cells. Furthermore, in studies
with Chang at the NCI, B-tropic virus
was isolated, and infection of murine cells
with this was shown to superimpose the
Meth A rejection antigen and the target
for cytotoxicity on those cells. However,
in immunoprecipitation tests, the specific-
ally cytotoxic syngeneic anti-Meth A
serum precipitated a common transforma-
tion related protein, p53, against which
an antibody-producing hybridoma had
now been produced. Also, in studies with
MCA-induced murine sarcomas, Pellis
reported the separation of two factors in
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3M KC1 extracts using preparative iso-
electric focusing. One of these (pl 5-96-
6-00, mol. wt 45,000-55,000) was specific-
ally protective in tumour-rejection tests,
whereas the other acidic component (pl
2.5) was enhancing in these assays.
Thomson discussed the use of the LAI
test to monitor the purification of TAA of
organ-related specificity from papain
digests of breast and colon carcinomas,
and Dickinson described his work on the
characterization of the common antigenic
polypeptide active in the MEM test and
released from tumour tissue by graded
acid hydrolysis. In studies with the rat
hepatoma D23, quantitative radioisotopic
antiglobulin assays indicated that about
8x 104 antigenic determinants were ex-
pressed per cell, so that the yield of anti-
genic protein after purification of papain
extracts by affinity to Concanavalin A,
and using immunoabsorbents with im-
mobilized syngeneic antibodies, was esti-
mated to be 500 (Price). Hannant re-
solved the problem of radiolabelling this
TSA by iodinating it when bound to its
specific antibody, thereby protecting the
antigenic determinant, and approxi-
mately 300% of this material specifically
rebound to appropriate syngeneic immune
antibodies. Lennox further described the
isolation of a deoxycholate-solubilized
TSA from an MCA-induced murine sar-
coma which was bound to wheat germ
lectin but not Concanavalin A, and on this
basis, was distinguished from H-2 anti-
gens.
In the session on the relationship of
TSA to histocompatibility antigens (HA)
Parmiani suggested that TSA activity
might be represented by the following:
(a) alien HA; (b) alien minor HA; (c)
modified HA; (d) a complex with HA;
(e) a complex with 3-2-microglobulin;
(f) a modified normal, non-HA structure.
Parmiani concluded that in his studies
with murine sarcomas, alien HA expressed
upon 3/10 lines were distinguishable from
TSA, and Law and Rogers were able to
separate TSA from alien HA and normal
H1-2 antigens by column chromatography.
Thomson suggested from his research on
human tumours that the organ-related
TAA reactive in LAI tests was either a
modified HL-A antigen, a complex with
HL-A or that the TAA epitope was linked
to /-2-microglobulin, and Baldwin con-
cluded that the TSA associated with rat
hepatomas was a modified minor HA.
The session on immunogenicity and
immunobiology of TSA was introduced by
Law, who described the powerful tumour
rejection-inducing properties of antigens
isolated from the murine tumours Meth A,
RBL5 and mKSA. The TSA isolated by
Pellis from 3M KCI extracts of MCA-
induced murine sarcomas were less effec-
tive in immunization experiments. Im-
munoprotection was evident only within
a narrow immunizing dose range, and
spleen cells from immune donors were
active in tumour neutralization tests,
though the time at which effector cells
were taken after antigen immunization
was critical in determining the outcome
of this experiment. Membrane fractions or
isolated TSA from the rat hepatoma D23
were essentially non-protective in im-
munoprotection assays, and for effective
immunization it was necessary to present
the TSA upon an attenuated cell retaining
a residual metabolic activity (Price).
Hannant, however, demonstrated that it
was possible to reveal the tumour rejec-
tion-induced activity of solubilized hepat-
oma D23 TSA in rats which had been pre-
treated with cyclophosphamide. Law con-
cluded that the major factors influencing
the immunogenicity of acellular antigen
preparations from different tumours were
(a) variations in the mode of antigen
extraction; (b) adverseimmunosuppressive
or immune deviation effects which are pre-
ferentially observed with weak TSA, and
(c) there may be structural differences be-
tween TSA from different tumour models
which influence the processing of antigen
by the host and direct the immune system
towards tumour-inhibitory or enhancing
responses (Law and Price).
Law closed the workshop by emphasiz-
ing that TSAs were being purified con-
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siderably now and, although there were
differences between the many tumours
studied, the delegates were aware of these
problems and work was proceeding in an
environment in which these problems
are being resolved.
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